Erbitux Articles
Repligen in profit for year-ending 2008
23 June 2008
Stock Commentary - New York week to June 2, 2008
9 June 2008
Erbitux gets nod from CHMP for new setting
9 June 2008
Stock Commentary - Europe - week to May 26, 2008
2 June 2008
Stock Commentary - New York week to May 12, 2008
19 May 2008
ImClone sees a $56M net loss in 1st-qtr 2008
5 May 2008
Stock Commentary - New York week to April 21, 2008
28 April 2008
Strong early data on Davanat plus 5-FU in CRC
10 March 2008
Stock Commentary - New York week to Feb 25, 2008
3 March 2008
UK's NICE asked to develop new clinical health guidance for DoH
18 February 2008
ImClone's 4th-qtr hurt by $60M settlement
14 February 2008
Plavix rebound cuts B-MS' 4th-qtr 2007 loss and offsets $797M charge
11 February 2008
wt-KRAS as Erbitux efficacy biomarker
4 February 2008
Stock Commentary - Europe - week to Dec 10, 2007
17 December 2007
ImClone/Sanofi sign $120M Yeda settlement
17 December 2007
Stock Commentary - New York week to Dec 3, 2007
10 December 2007
Merck KGaA seeks to expand Erbitux in mCRC
10 December 2007
Most UK NHS patients not told of drug options
26 November 2007
Erbitux improves overall survival in mCRC
26 November 2007
ImClone sees 3rd-qtr loss on legal charge
5 November 2007
Merck KGaA's net falls but beats forecasts
29 October 2007
Erbitux partners plan for Japan marketing
22 October 2007
Stock Commentary - New York week to Oct 8, 2007
15 October 2007
FDA clears update to Erbitux labeling
8 October 2007
14th annual ECCO conference hears exciting data on combination therapy with biologics
8 October 2007
Stock Commentary - Europe - week to Sept 17, 2007
24 September 2007
Stock Commentary - New York week to Sept 10, 2007
17 September 2007
Erbitux meets Ph III NSCLC trial endpoints
17 September 2007
ImClone to pay Repligen $65M in Erbitux case
17 September 2007
World Conference on Lung Cancer highlights important developments
17 September 2007
Merck KGaA seeks EU OK for Erbitux in mCRC
10 September 2007
FDA OKs second ImClone Erbitux plant
3 September 2007
ImClone's 2nd-qtr profit drops 14% to $319M
13 August 2007
ImClone and B-MS amend Erbitux deal
6 August 2007
Serono buy hits Merck KGaA 2nd-qtr profits, but still beats consensus, and sales leap 52%
30 July 2007
ImClone starts Ph II enrollment for IMC-A12
23 July 2007
Stock Commentary - New York - week to July 16, 2007
23 July 2007
Stock Commentary - Europe - week to July 16, 2007
23 July 2007
Merck KGaA to join Germany's DAX
18 June 2007
Erbitux sets new record for RMSCCHN survival
11 June 2007
Stock Commentary - New York week to May 21, 2007
28 May 2007
Stock Commentary - New York week to May 7, 2007
14 May 2007
ImClone sees 1st-qtr profit slump
7 May 2007
Amgen's 1st-qtr 2007 net profits up 11%
30 April 2007
Merck KGaA attributes 1st-qtr loss to Serono buy
30 April 2007
Erbitux falls short in colorectal cancer trial
23 April 2007
Erbitux fails in Ph III pancreatic cancer trial
16 April 2007
Stock Commentary - New York week to April 9
16 April 2007
Stock Commentary - Europe - week to April 9
16 April 2007
Erbitux increases overall survival in SCCHN
16 April 2007
Stock Commentary - Europe - week to March 26
2 April 2007
Stock Commentary - New York week to March 26
2 April 2007
NICE rejects Erbitux for latest cancer indication
12 February 2007
Erbitux submitted for advanced CRC in Japan
12 February 2007
ImClone's profits reach $46M on Erbitux sales
5 February 2007
B-MS swings to loss in 4th qtr due to Plavix
5 February 2007
Stock Commentary - New York week to Aug 15
29 January 2007
UK's NICE rejects Erbitux in advanced CRC
29 January 2007
Strong data for Erbitux on flexible dosing
29 January 2007
Merck KGaA's 2006 results as expected
29 January 2007
Stock Commentary - Europe - week to Jan 15, 2007
22 January 2007
Stock Commentary - New York week to Jan 8, 2007
15 January 2007
Merck Serono SA officially launched
15 January 2007
Stock Commentary - New York week to Nov 13, 2006
20 November 2006
ImClone/B-MS/Meck KGaA's Erbitux will reach $250M in 2015
20 November 2006
Introgen gains rights to therapies combining EGFr inhibitors
13 November 2006
Stock Commentary - Europe - week to Nov 6, 2006
13 November 2006
Merck KGaA sees positive Erbitux data
13 November 2006
ImClone's 3rd-qtr income rises 88%
13 November 2006
Hana Biosci in-licenses menadione
23 October 2006
Merck KGaA wins right to appeal NICE decision on Erbitux
23 October 2006
Stock Commentary - Europe - week to Oct 2, 2006
9 October 2006
FDA clears Amgen's cancer drug Vectibix
9 October 2006
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
